

# Adam S Garden

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1401799/publications.pdf>

Version: 2024-02-01

373  
papers

27,343  
citations

5268

83  
h-index

7745

150  
g-index

381  
all docs

381  
docs citations

381  
times ranked

17653  
citing authors

#	ARTICLE	IF	CITATIONS
1	A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000, 48, 7-16.	0.8	1,222
2	Factors Associated With Severe Late Toxicity After Concurrent Chemoradiation for Locally Advanced Head and Neck Cancer: An RTOG Analysis. <i>Journal of Clinical Oncology</i> , 2008, 26, 3582-3589.	1.6	1,188
3	Randomized Phase III Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Stage III to IV Head and Neck Carcinoma: RTOG 0522. <i>Journal of Clinical Oncology</i> , 2014, 32, 2940-2950.	1.6	697
4	Quantification of volumetric and geometric changes occurring during fractionated radiotherapy for head-and-neck cancer using an integrated CT/linear accelerator system. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 59, 960-970.	0.8	643
5	Intensity-Modulated Radiation Therapy With or Without Chemotherapy for Nasopharyngeal Carcinoma: Radiation Therapy Oncology Group Phase II Trial 0225. <i>Journal of Clinical Oncology</i> , 2009, 27, 3684-3690.	1.6	607
6	Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study. <i>Lancet Oncology</i> , The, 2016, 17, 440-451.	10.7	607
7	Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 51, 571-578.	0.8	566
8	Validation of an accelerated "demonstrated" algorithm for deformable image registration in radiation therapy. <i>Physics in Medicine and Biology</i> , 2005, 50, 2887-2905.	3.0	537
9	Evaluation of the dose for postoperative radiation therapy of head and neck cancer: First report of a prospective randomized trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 1993, 26, 3-11.	0.8	479
10	Human Papillomavirus and Overall Survival After Progression of Oropharyngeal Squamous Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 3365-3373.	1.6	449
11	Risk, Outcomes, and Costs of Radiation-Induced Oral Mucositis Among Patients With Head-and-Neck Malignancies. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 68, 1110-1120.	0.8	405
12	The influence of positive margins and nerve invasion in adenoid cystic carcinoma of the head and neck treated with surgery and radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 1995, 32, 619-626.	0.8	401
13	Multi-Institutional Trial of Accelerated Hypofractionated Intensity-Modulated Radiation Therapy for Early-Stage Oropharyngeal Cancer (RTOG 00-22). <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, 1333-1338.	0.8	336
14	Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy. <i>Cancer</i> , 2008, 113, 2704-2713.	4.1	310
15	Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial. <i>Lancet Oncology</i> , The, 2012, 13, 172-180.	10.7	291
16	Carcinoma of the nasopharynx treated by radiotherapy alone: Determinants of local and regional control. <i>International Journal of Radiation Oncology Biology Physics</i> , 1997, 37, 985-996.	0.8	265
17	Induction Chemotherapy and Cetuximab for Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Results From a Phase II Prospective Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 8-14.	1.6	234
18	Parathyroid carcinoma: A 22-year experience. <i>Head and Neck</i> , 2004, 26, 716-726.	2.0	233

#	ARTICLE	IF	CITATIONS
19	Measuring head and neck cancer symptom burden: The development and validation of the M. D. Anderson symptom inventory, head and neck module. <i>Head and Neck</i> , 2007, 29, 923-931.	2.0	227
20	IMRT Reirradiation of Head and Neck Cancer—Disease Control and Morbidity Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 73, 399-409.	0.8	218
21	Radiation-induced Xerostomia in patients with head and neck cancer: Pathogenesis, impact on quality of life, and management. <i>Head and Neck</i> , 2004, 26, 796-807.	2.0	213
22	Osteoradionecrosis and Radiation Dose to the Mandible in Patients With Oropharyngeal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 415-420.	0.8	209
23	Cerebrovascular Disease Risk in Older Head and Neck Cancer Patients After Radiotherapy. <i>Journal of Clinical Oncology</i> , 2008, 26, 5119-5125.	1.6	206
24	Adaptive Radiotherapy for Head-and-Neck Cancer: Initial Clinical Outcomes From a Prospective Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 986-993.	0.8	205
25	Evaluation of cognitive function in patients with limited small cell lung cancer prior to and shortly following prophylactic cranial irradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 1995, 33, 179-182.	0.8	199
26	Final Results of Local-Regional Control and Late Toxicity of RTOG 9003: A Randomized Trial of Altered Fractionation Radiation for Locally Advanced Head and Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 13-20.	0.8	198
27	Postoperative radiotherapy for cutaneous melanoma of the head and neck region. <i>International Journal of Radiation Oncology Biology Physics</i> , 1994, 30, 795-798.	0.8	194
28	TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group. <i>Lancet Oncology</i> , The, 2007, 8, 613-624.	10.7	191
29	Adult rhabdomyosarcoma. <i>Cancer</i> , 2002, 95, 377-388.	4.1	189
30	Sinonasal malignancies with neuroendocrine differentiation. <i>Cancer</i> , 2004, 101, 2567-2573.	4.1	187
31	Cutaneous angiosarcoma of the head and neck. A therapeutic dilemma. <i>Cancer</i> , 1995, 76, 319-327.	4.1	185
32	Association of Body Composition With Survival and Locoregional Control of Radiotherapy-Treated Head and Neck Squamous Cell Carcinoma. <i>JAMA Oncology</i> , 2016, 2, 782.	7.1	185
33	Preliminary Results of Radiation Therapy Oncology Group 97-03: A Randomized Phase II Trial of Concurrent Radiation and Chemotherapy for Advanced Squamous Cell Carcinomas of the Head and Neck. <i>Journal of Clinical Oncology</i> , 2004, 22, 2856-2864.	1.6	177
34	Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer — A case matched analysis. <i>Radiotherapy and Oncology</i> , 2016, 120, 48-55.	0.6	177
35	Postoperative radiotherapy for malignant tumors of the parotid gland. <i>International Journal of Radiation Oncology Biology Physics</i> , 1997, 37, 79-85.	0.8	176
36	Postoperative radiation therapy for malignant tumors of minor salivary glands. Outcome and patterns of failure. <i>Cancer</i> , 1994, 73, 2563-2569.	4.1	172

#	ARTICLE	IF	CITATIONS
37	Beam Path Toxicities to Non-Target Structures During Intensity-Modulated Radiation Therapy for Head and Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 747-755.	0.8	168
38	Adaptive radiotherapy for head and neck cancer—Dosimetric results from a prospective clinical trial. <i>Radiotherapy and Oncology</i> , 2013, 106, 80-84.	0.6	168
39	Multiple regions-of-interest analysis of setup uncertainties for head-and-neck cancer radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 64, 1559-1569.	0.8	165
40	Prognostic factors in mucoepidermoid carcinoma of the salivary glands. <i>Cancer</i> , 2012, 118, 3928-3936.	4.1	165
41	Carcinoma of the nasopharynx treated by radiotherapy alone: determinants of distant metastasis and survival. <i>Radiotherapy and Oncology</i> , 1997, 43, 53-61.	0.6	159
42	Prospective Risk-Adjusted [ <sup>18</sup> F]Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography Assessment of Radiation Response in Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 2509-2515.	1.6	156
43	Candidate Dosimetric Predictors of Long-Term Swallowing Dysfunction After Oropharyngeal Intensity-Modulated Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 1356-1365.	0.8	156
44	Practice Recommendations for Risk-Adapted Head and Neck Cancer Radiation Therapy During the COVID-19 Pandemic: An ASTRO-ESTRO Consensus Statement. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 618-627.	0.8	156
45	Concomitant Boost Radiation Plus Concurrent Cisplatin for Advanced Head and Neck Carcinomas: Radiation Therapy Oncology Group Phase II Trial 99-14. <i>Journal of Clinical Oncology</i> , 2005, 23, 3008-3015.	1.6	151
46	An evolution in demographics, treatment, and outcomes of oropharyngeal cancer at a major cancer center. <i>Cancer</i> , 2013, 119, 81-89.	4.1	145
47	Postoperative External Beam Radiotherapy for Differentiated Thyroid Cancer: Outcomes and Morbidity With Conformal Treatment. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 74, 1083-1091.	0.8	143
48	Neck surgery in patients with primary oropharyngeal cancer treated by radiotherapy. <i>Head and Neck</i> , 1996, 18, 552-559.	2.0	134
49	Results of radiotherapy for T2N0 glottic carcinoma: does the “2x stand for twice-daily treatment?”. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 55, 322-328.	0.8	130
50	Disease-control rates following intensity-modulated radiation therapy for small primary oropharyngeal carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 438-444.	0.8	130
51	Parotid Gland Dose in Intensity-Modulated Radiotherapy for Head and Neck Cancer: Is What You Plan What You Get?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 1290-1296.	0.8	130
52	Improved survival using intensity-modulated radiation therapy in head and neck cancers: A SEER-Medicare analysis. <i>Cancer</i> , 2014, 120, 702-710.	4.1	129
53	Outcome and patterns of failure following limited-volume irradiation for malignant astrocytomas. <i>Radiotherapy and Oncology</i> , 1991, 20, 99-110.	0.6	128
54	Multifield Optimization Intensity Modulated Proton Therapy for Head and Neck Tumors: A Translation to Practice. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 846-853.	0.8	128

#	ARTICLE	IF	CITATIONS
55	Reirradiation of Head and Neck Cancers With Proton Therapy: Outcomes and Analyses. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 30-41.	0.8	123
56	Postoperative radiation for squamous cell carcinoma metastatic to cervical lymph nodes from an unknown primary site: Outcomes and patterns of failure. , 1998, 20, 674-681.		122
57	Intensity Modulated Proton Therapy Versus Intensity Modulated Photon Radiation Therapy for Oropharyngeal Cancer: First Comparative Results of Patient-Reported Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 1107-1114.	0.8	121
58	A multinational, randomized phase iii trial of iseganan hcl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 58, 674-681.	0.8	119
59	Minor salivary gland tumors of the palate: Clinical and pathologic correlates of outcome. <i>Laryngoscope</i> , 1995, 105, 1155-1160.	2.0	116
60	Combined Interferon-Alfa, 13-cis-Retinoic Acid, and Alpha-Tocopherol in Locally Advanced Head and Neck Squamous Cell Carcinoma: Novel Bioadjuvant Phase II Trial. <i>Journal of Clinical Oncology</i> , 2001, 19, 3010-3017.	1.6	115
61	Prognosis and risk factors for early-stage adenoid cystic carcinoma of the major salivary glands. <i>Cancer</i> , 2012, 118, 2872-2878.	4.1	115
62	Comparison of 2D Radiographic Images and 3D Cone Beam Computed Tomography for Positioning Head-and-Neck Radiotherapy Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 916-925.	0.8	112
63	Mucositis-Related Morbidity and Resource Utilization in Head and Neck Cancer Patients Receiving Radiation Therapy With or Without Chemotherapy. <i>Journal of Pain and Symptom Management</i> , 2009, 38, 522-532.	1.2	112
64	Neoadjuvant BRAF- and Immune-Directed Therapy for Anaplastic Thyroid Carcinoma. <i>Thyroid</i> , 2018, 28, 945-951.	4.5	111
65	Adjuvant irradiation for cervical lymph node metastases from melanoma. <i>Cancer</i> , 2003, 97, 1789-1796.	4.1	110
66	A multi-institution pooled analysis of gastrostomy tube dependence in patients with oropharyngeal cancer treated with definitive intensity-modulated radiotherapy. <i>Cancer</i> , 2015, 121, 294-301.	4.1	109
67	Patterns of symptom burden during radiotherapy or concurrent chemoradiotherapy for head and neck cancer: A prospective analysis using the University of Texas MD Anderson Cancer Center Symptom Inventory-Head and Neck Module. <i>Cancer</i> , 2014, 120, 1975-1984.	4.1	106
68	Intensity modulated proton therapy (IMPT) – The future of IMRT for head and neck cancer. <i>Oral Oncology</i> , 2019, 88, 66-74.	1.5	103
69	Intensity-modulated proton therapy for nasopharyngeal carcinoma: Decreased radiation dose to normal structures and encouraging clinical outcomes. <i>Head and Neck</i> , 2016, 38, E1886-95.	2.0	102
70	Long-Term Results of Concomitant Boost Radiation Plus Concurrent Cisplatin for Advanced Head and Neck Carcinomas: A Phase II Trial of the Radiation Therapy Oncology Group (RTOG 99-14). <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 1351-1355.	0.8	101
71	Adherence to preventive exercises and self-reported swallowing outcomes in post-radiation head and neck cancer patients. <i>Head and Neck</i> , 2013, 35, 1707-1712.	2.0	101
72	Long-term outcomes after surgical or nonsurgical initial therapy for patients with T4 squamous cell carcinoma of the larynx: A 3-decade survey. <i>Cancer</i> , 2015, 121, 1608-1619.	4.1	100

#	ARTICLE	IF	CITATIONS
73	Reirradiation of Head and Neck Cancers With Intensity Modulated Radiation Therapy: Outcomes and Analyses. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 1117-1131.	0.8	100
74	Patterns of Disease Recurrence Following Treatment of Oropharyngeal Cancer With Intensity Modulated Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 941-947.	0.8	99
75	Performance Evaluation of Automatic Anatomy Segmentation Algorithm on Repeat or Four-Dimensional Computed Tomography Images Using Deformable Image Registration Method. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 210-219.	0.8	98
76	Phase III Trial of an Emulsion Containing Trolamine for the Prevention of Radiation Dermatitis in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck: Results of Radiation Therapy Oncology Group Trial 99-13. <i>Journal of Clinical Oncology</i> , 2006, 24, 2092-2097.	1.6	97
77	Prospective randomized double-blind study of atlas-based organ-at-risk autosegmentation-assisted radiation planning in head and neck cancer. <i>Radiotherapy and Oncology</i> , 2014, 112, 321-325.	0.6	96
78	Unilateral Radiotherapy for the Treatment of Tonsil Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 204-209.	0.8	94
79	Simple Carotid-Sparing Intensity-Modulated Radiotherapy Technique and Preliminary Experience for T1-2 Glottic Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 455-461.	0.8	89
80	Outcomes and patterns of care of patients with locally advanced oropharyngeal carcinoma treated in the early 21st century. <i>Radiation Oncology</i> , 2013, 8, 21.	2.7	89
81	Superior sulcus tumors: Treatment selection and results for 85 patients without metastasis (Mo) at presentation. <i>International Journal of Radiation Oncology Biology Physics</i> , 1990, 19, 31-36.	0.8	88
82	Spot-scanning beam proton therapy vs intensity-modulated radiation therapy for ipsilateral head and neck malignancies: A treatment planning comparison. <i>Medical Dosimetry</i> , 2013, 38, 390-394.	0.9	88
83	Clinical Outcomes and Patterns of Disease Recurrence After Intensity Modulated Proton Therapy for Oropharyngeal Squamous Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 360-367.	0.8	88
84	Is concurrent chemoradiation the treatment of choice for all patients with Stage III or IV head and neck carcinoma?. <i>Cancer</i> , 2004, 100, 1171-1178.	4.1	87
85	Longitudinal evaluation of the oral mucositis weekly questionnaire-head and neck cancer, a patient-reported outcomes questionnaire. <i>Cancer</i> , 2007, 109, 1914-1922.	4.1	86
86	Postoperative Radiotherapy for Maxillary Sinus Cancer: Long-Term Outcomes and Toxicities of Treatment. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 68, 719-730.	0.8	86
87	Final Report of a Prospective Randomized Trial to Evaluate the Dose-Response Relationship for Postoperative Radiation Therapy and Pathologic Risk Groups in Patients With Head and Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 1002-1011.	0.8	86
88	Beyond mean pharyngeal constrictor dose for beam path toxicity in non-target swallowing muscles: Dose-volume correlates of chronic radiation-associated dysphagia (RAD) after oropharyngeal intensity modulated radiotherapy. <i>Radiotherapy and Oncology</i> , 2016, 118, 304-314.	0.6	85
89	Determining optimal clinical target volume margins in head-and-neck cancer based on microscopic extracapsular extension of metastatic neck nodes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 64, 678-683.	0.8	83
90	DNA Repair Biomarker Profiling of Head and Neck Cancer: Ku80 Expression Predicts Locoregional Failure and Death following Radiotherapy. <i>Clinical Cancer Research</i> , 2011, 17, 2035-2043.	7.0	81



#	ARTICLE	IF	CITATIONS
91	Anaplastic thyroid cancer: Clinical outcomes with conformal radiotherapy. <i>Head and Neck</i> , 2010, 32, 829-836.	2.0	80
92	Clinical Practice Guidance for Radiotherapy Planning After Induction Chemotherapy in Locoregionally Advanced Head-and-Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 725-733.	0.8	80
93	Postoperative radiotherapy for advanced medullary thyroid cancer—Local disease control in the modern era. <i>Head and Neck</i> , 2008, 30, 883-888.	2.0	78
94	Complications of radiotherapy in laryngopharyngeal cancer. <i>Cancer</i> , 2009, 115, 4636-4644.	4.1	78
95	Toward a model-based patient selection strategy for proton therapy: External validation of photon-derived normal tissue complication probability models in a head and neck proton therapy cohort. <i>Radiotherapy and Oncology</i> , 2016, 121, 381-386.	0.6	78
96	Management of nonsinonasal neuroendocrine carcinomas of the head and neck. <i>Cancer</i> , 2003, 98, 2322-2328.	4.1	77
97	Intensity-modulated radiation therapy (IMRT) of cancers of the head and neck: Comparison of split-field and whole-field techniques. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 63, 1000-1005.	0.8	76
98	Proton Therapy Reduces Treatment-Related Toxicities for Patients with Nasopharyngeal Cancer: A Case-Match Control Study of Intensity-Modulated Proton Therapy and Intensity-Modulated Photon Therapy. <i>International Journal of Particle Therapy</i> , 2015, 2, 19-28.	1.8	76
99	Intensity-Modulated Radiotherapy for Cervical Node Squamous Cell Carcinoma Metastases From Unknown Head-and-Neck Primary Site: M. D. Anderson Cancer Center Outcomes and Patterns of Failure. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 1005-1010.	0.8	75
100	Laryngeal preservation by induction chemotherapy plus radiotherapy in locally advanced head and neck cancer: The M. D. Anderson cancer center experience. <i>Head and Neck</i> , 1994, 16, 39-44.	2.0	74
101	Intensity-modulated proton therapy and osteoradionecrosis in oropharyngeal cancer. <i>Radiotherapy and Oncology</i> , 2017, 123, 401-405.	0.6	73
102	The M. D. Anderson Symptom Inventory—Head and Neck Module, a Patient-Reported Outcome Instrument, Accurately Predicts the Severity of Radiation-Induced Mucositis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 1355-1361.	0.8	72
103	Automatic detection of contouring errors using convolutional neural networks. <i>Medical Physics</i> , 2019, 46, 5086-5097.	3.0	72
104	Elective radiotherapy provides regional control for patients with cutaneous melanoma of the head and neck. <i>Cancer</i> , 2004, 100, 383-389.	4.1	71
105	Importance of patient examination to clinical quality assurance in head and neck radiation oncology. <i>Head and Neck</i> , 2006, 28, 967-973.	2.0	70
106	Base-of-tongue carcinoma: Treatment results using concomitant boost radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 1995, 33, 289-296.	0.8	69
107	Dose-volume correlates of mandibular osteoradionecrosis in Oropharynx cancer patients receiving intensity-modulated radiotherapy: Results from a case-matched comparison. <i>Radiotherapy and Oncology</i> , 2017, 124, 232-239.	0.6	69
108	Postoperative radiotherapy for malignant tumors of the submandibular gland. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 51, 952-958.	0.8	68

#	ARTICLE	IF	CITATIONS
109	Radiation Therapy for Nonmelanoma Skin Carcinomas. <i>Clinics in Plastic Surgery</i> , 1997, 24, 719-729.	1.5	65
110	Ethmoid sinus carcinomas: natural history and treatment results. <i>Radiotherapy and Oncology</i> , 1998, 49, 21-27.	0.6	65
111	Primary carcinoma of the female urethra results of radiation therapy. <i>Cancer</i> , 1993, 71, 3102-3108.	4.1	64
112	Early squamous cell carcinoma of the hypopharynx: Outcomes of treatment with radiation alone to the primary disease. , 1996, 18, 317-322.		64
113	Metabolic Tumor Volume as a Prognostic Imaging-Based Biomarker for Head-and-Neck Cancer: Pilot Results From Radiation Therapy Oncology Group Protocol 0522. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 721-729.	0.8	64
114	Proposed Staging System for Patients With HPV-Related Oropharyngeal Cancer Based on Nasopharyngeal Cancer N Categories. <i>Journal of Clinical Oncology</i> , 2016, 34, 1848-1854.	1.6	64
115	Impact of Neoadjuvant Durvalumab with or without Tremelimumab on CD8+ Tumor Lymphocyte Density, Safety, and Efficacy in Patients with Oropharynx Cancer: CIAO Trial Results. <i>Clinical Cancer Research</i> , 2020, 26, 3211-3219.	7.0	64
116	Target coverage for head and neck cancers treated with IMRT: review of clinical experiences. <i>Seminars in Radiation Oncology</i> , 2004, 14, 103-109.	2.2	62
117	Radiation therapy for early-stage carcinoma of the oropharynx. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 59, 743-751.	0.8	62
118	Outcomes of malignant tumors of the lacrimal apparatus. <i>Cancer</i> , 2011, 117, 2801-2810.	4.1	62
119	Prediction of Neck Dissection Requirement After Definitive Radiotherapy for Head-and-Neck Squamous Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, e367-e374.	0.8	62
120	Relation between the level of lymph node metastasis and survival in locally advanced head and neck squamous cell carcinoma. <i>Cancer</i> , 2016, 122, 534-545.	4.1	62
121	Dosimetric advantages of intensity-modulated proton therapy for oropharyngeal cancer compared with intensity-modulated radiation: A case-matched control analysis. <i>Medical Dosimetry</i> , 2016, 41, 189-194.	0.9	62
122	Can positron emission tomography improve the quality of care for head-and-neck cancer patients?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 51, 4-9.	0.8	61
123	Pretreatment Quality of Life Predicts for Locoregional Control in Head and Neck Cancer Patients: A Radiation Therapy Oncology Group Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 353-360.	0.8	61
124	Hypopharyngeal Dose Is Associated With Severe Late Toxicity in Locally Advanced Head-and-Neck Cancer: An RTOG Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, 983-989.	0.8	61
125	Selective vs Modified Radical Neck Dissection and Postoperative Radiotherapy vs Observation in the Treatment of Squamous Cell Carcinoma of the Oral Tongue. <i>JAMA Otolaryngology</i> , 2005, 131, 874.	1.2	60
126	Phase I/II Study of Docetaxel, Cisplatin, and Concomitant Boost Radiation for Locally Advanced Squamous Cell Cancer of the Head and Neck. <i>Journal of Clinical Oncology</i> , 2006, 24, 4163-4169.	1.6	59



#	ARTICLE	IF	CITATIONS
127	Disadvantage of Men Living Alone Participating in Radiation Therapy Oncology Group Head and Neck Trials. <i>Journal of Clinical Oncology</i> , 2006, 24, 4177-4183.	1.6	59
128	Quality Assurance Assessment of Diagnostic and Radiation Therapyâ€“Simulation CT Image Registration for Head and Neck Radiation Therapy: Anatomic Region of Interestâ€“based Comparison of Rigid and Deformable Algorithms. <i>Radiology</i> , 2015, 274, 752-763.	7.3	58
129	Induction chemotherapy followed by radiotherapy versus radiotherapy alone in patients with advanced nasopharyngeal carcinoma. , 1997, 79, 1279-1286.		56
130	Electron conformal radiotherapy using bolus and intensity modulation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 53, 1023-1037.	0.8	56
131	Risk of osteoradionecrosis after extraction of impacted third molars in irradiated head and neck cancer patients. <i>Journal of Oral and Maxillofacial Surgery</i> , 2004, 62, 139-144.	1.2	56
132	Outcomes after radiotherapy for squamous cell carcinoma of the eyelid. <i>Cancer</i> , 2008, 112, 111-118.	4.1	56
133	Long-Term Radiotherapy Outcomes for Nasal Cavity and Septal Cancers. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 401-406.	0.8	55
134	Radiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma: Outcomes from the National Cancer Data Base. <i>Cancer</i> , 2017, 123, 1653-1661.	4.1	55
135	Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck. <i>Cancer</i> , 2002, 95, 322-330.	4.1	54
136	Beam path toxicity in candidate organs-at-risk: Assessment of radiation emetogenesis for patients receiving head and neck intensity modulated radiotherapy. <i>Radiotherapy and Oncology</i> , 2014, 111, 281-288.	0.6	54
137	Prospective Qualitative and Quantitative Analysis of Real-Time Peer Review Quality Assurance Rounds Incorporating Direct Physical Examination for Head and Neck Cancer Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 532-540.	0.8	54
138	Radiation Therapy for Early Stage (T1-T2) Sarcomatoid Carcinoma of True Vocal Cords: Outcomes and Patterns of Failure. <i>Laryngoscope</i> , 1998, 108, 760-763.	2.0	53
139	Phase I/II Trial of Radiation With Chemotherapy â€œBoostâ€•for Advanced Squamous Cell Carcinomas of the Head and Neck: Toxicities and Responses. <i>Journal of Clinical Oncology</i> , 1999, 17, 2390-2390.	1.6	53
140	Head and neck carcinoma in the United States. <i>Cancer</i> , 2012, 118, 5783-5792.	4.1	53
141	Evaluating the impact of patient, tumor, and treatment characteristics on the development of jaw complications in patients treated for oral cancers: A SEER-Medicare analysis. <i>Head and Neck</i> , 2013, 35, 1599-1605.	2.0	52
142	Hyperfractionated radiation in the treatment of squamous cell carcinomas of the head and neck: A comparison of two fractionation schedules. <i>International Journal of Radiation Oncology Biology Physics</i> , 1995, 31, 493-502.	0.8	51
143	Intravoxel incoherent motion imaging kinetics during chemoradiotherapy for human papillomavirus-associated squamous cell carcinoma of the oropharynx: preliminary results from a prospective pilot study. <i>NMR in Biomedicine</i> , 2015, 28, 1645-1654.	2.8	51
144	Auto-delineation of oropharyngeal clinical target volumes using 3D convolutional neural networks. <i>Physics in Medicine and Biology</i> , 2018, 63, 215026.	3.0	51

#	ARTICLE	IF	CITATIONS
145	Dysphagia After Primary Transoral Robotic Surgery With Neck Dissection vs Nonsurgical Therapy in Patients With Low- to Intermediate-Risk Oropharyngeal Cancer. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2019, 145, 1053.	2.2	51
146	Imaging and clinical data archive for head and neck squamous cell carcinoma patients treated with radiotherapy. <i>Scientific Data</i> , 2018, 5, 180173.	5.3	51
147	The role of interstitial brachytherapy with salvage surgery for the management of recurrent head and neck cancers. <i>Cancer</i> , 2007, 109, 2052-2057.	4.1	49
148	The impact of radiographic retropharyngeal adenopathy in oropharyngeal cancer. <i>Cancer</i> , 2013, 119, 3162-3169.	4.1	49
149	A Multidisciplinary Orbit-Sparing Treatment Approach That Includes Proton Therapy for Epithelial Tumors of the Orbit and Ocular Adnexa. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 344-352.	0.8	49
150	Generating High-Quality Lymph Node Clinical Target Volumes for Head and Neck Cancer Radiation Therapy Using a Fully Automated Deep Learning-Based Approach. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 801-812.	0.8	49
151	Intraarterial cisplatin with intravenous paclitaxel and ifosfamide as an organ-preservation approach in patients with paranasal sinus carcinoma. <i>Cancer</i> , 2003, 98, 2214-2223.	4.1	48
152	Concomitant boost radiotherapy for squamous carcinoma of the tonsillar fossa. <i>International Journal of Radiation Oncology Biology Physics</i> , 1997, 39, 127-135.	0.8	47
153	New thoughts on the pathobiology of regimen-related mucosal injury. <i>Supportive Care in Cancer</i> , 2006, 14, 516-518.	2.2	47
154	Durable Long-Term Remission With Chemotherapy Alone for Stage II to IV Laryngeal Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 1976-1982.	1.6	47
155	The Insurance Approval Process for Proton Radiation Therapy: A Significant Barrier to Patient Care. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 724-733.	0.8	47
156	Long-Term, Prospective Performance of the MD Anderson Dysphagia Inventory in Low-Intermediate Risk Oropharyngeal Carcinoma After Intensity Modulated Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 700-708.	0.8	46
157	Postoperative Adjuvant External-Beam Radiation Therapy for Cancers of the Eyelid and Conjunctiva. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2008, 24, 444-449.	0.8	45
158	Prognostic Factors Associated With Decreased Survival in Patients With Acinic Cell Carcinoma. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2013, 139, 1195.	2.2	45
159	Open-Label, Long-Term Safety Study of Cevimeline in the Treatment of Postirradiation Xerostomia. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 1369-1376.	0.8	44
160	Gastrostomy in oropharyngeal cancer patients with ERCC4 (XPF) germline variants. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 62, 665-671.	0.8	43
161	Outcomes after radiotherapy for basaloid squamous cell carcinoma of the head and neck. <i>Cancer</i> , 2008, 112, 2698-2709.	4.1	43
162	Long-term functional and survival outcomes after induction chemotherapy and risk-based definitive therapy for locally advanced squamous cell carcinoma of the head and neck. <i>Head and Neck</i> , 2014, 36, 474-480.	2.0	43

#	ARTICLE	IF	CITATIONS
163	A multimodality segmentation framework for automatic target delineation in head and neck radiotherapy. <i>Medical Physics</i> , 2015, 42, 5310-5320.	3.0	43
164	Melanoma metastatic to cervical lymph nodes: Can radiotherapy replace formal dissection after local excision of nodal disease?. <i>Head and Neck</i> , 2005, 27, 718-721.	2.0	42
165	Neoadjuvant chemotherapy for locoregionally advanced squamous cell carcinoma of the paranasal sinuses. <i>Cancer</i> , 2021, 127, 1788-1795.	4.1	42
166	Controversies in Surgical Management of the Node-Positive Neck After Chemoradiation. <i>Seminars in Radiation Oncology</i> , 2009, 19, 24-28.	2.2	41
167	Longitudinal oncology registry of head and neck carcinoma (LORHAN). <i>Cancer</i> , 2011, 117, 1679-1686.	4.1	41
168	Identifying Early Dehydration Risk With Home-Based Sensors During Radiation Treatment: A Feasibility Study on Patients With Head and Neck Cancer. <i>Journal of the National Cancer Institute Monographs</i> , 2013, 2013, 162-168.	2.1	41
169	The role of elective nodal irradiation for esthesioneuroblastoma patients with clinically negative neck. <i>Practical Radiation Oncology</i> , 2016, 6, 241-247.	2.1	41
170	Magnetic Resonance-based Response Assessment and Dose Adaptation in Human Papilloma Virus Positive Tumors of the Oropharynx treated with Radiotherapy (MR-ADAPTOR): An R-IDEAL stage 2a-2b/Bayesian phase II trial. <i>Clinical and Translational Radiation Oncology</i> , 2018, 13, 19-23.	1.7	41
171	Comparison between normal tissue reactions and local tumor control in head and neck cancer patients treated by definitive radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 1996, 35, 455-462.	0.8	40
172	Early Postoperative Paclitaxel Followed by Concurrent Paclitaxel and Cisplatin With Radiation Therapy for Patients With Resected High-Risk Head and Neck Squamous Cell Carcinoma: Report of the Phase II Trial RTOG 0024. <i>Journal of Clinical Oncology</i> , 2009, 27, 4727-4732.	1.6	40
173	A choice of radionuclide: Comparative outcomes and toxicity of ruthenium-106 and iodine-125 in the definitive treatment of uveal melanoma. <i>Practical Radiation Oncology</i> , 2015, 5, e169-e176.	2.1	40
174	Carcinomas of the nasal cavity. <i>Radiotherapy and Oncology</i> , 1992, 24, 163-168.	0.6	39
175	Submandibular gland-sparing radiation therapy for locally advanced oropharyngeal squamous cell carcinoma: patterns of failure and xerostomia outcomes. <i>Radiation Oncology</i> , 2014, 9, 255.	2.7	39
176	Does induction chemotherapy have a role in the management of nasopharyngeal carcinoma? Results of treatment in the era of computerized tomography. <i>International Journal of Radiation Oncology Biology Physics</i> , 1996, 36, 1005-1012.	0.8	38
177	Olfactory Neuroblastoma and Neuroendocrine Carcinoma of the Anterior Skull Base: Treatment Results at the M.D. Anderson Cancer Center. <i>Skull Base</i> , 1996, 6, 1-8.	0.4	37
178	Predicting two-year longitudinal MD Anderson Dysphagia Inventory outcomes after intensity modulated radiotherapy for locoregionally advanced oropharyngeal carcinoma. <i>Laryngoscope</i> , 2017, 127, 842-848.	2.0	37
179	A Phase II study of docetaxel and carboplatin as neoadjuvant therapy for nasopharyngeal carcinoma with early T status and advanced N status. <i>Cancer</i> , 2004, 100, 991-998.	4.1	36
180	Combination of radiotherapy with EGFR antagonists for head and neck carcinoma. <i>International Journal of Clinical Oncology</i> , 2007, 12, 99-110.	2.2	36

#	ARTICLE	IF	CITATIONS
181	Definitive proton radiation therapy and concurrent cisplatin for unresectable head and neck adenoid cystic carcinoma: A series of 9 cases and a critical review of the literature. <i>Head and Neck</i> , 2016, 38, E1472-80.	2.0	36
182	Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Locally Advanced Head and Neck Carcinoma: NRG Oncology Radiation Therapy Oncology Group 0522. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 687-699.	0.8	35
183	Assessment of shoulder position variation and its impact on IMRT and VMAT doses for head and neck cancer. <i>Radiation Oncology</i> , 2012, 7, 19.	2.7	34
184	Methodology for analysis and reporting patterns of failure in the Era of IMRT: head and neck cancer applications. <i>Radiation Oncology</i> , 2016, 11, 95.	2.7	34
185	Intensity-modulated radiotherapy: Is xerostomia still prevalent?. <i>Current Oncology Reports</i> , 2005, 7, 131-136.	4.0	33
186	The Effect of Dental Artifacts, Contrast Media, and Experience on Interobserver Contouring Variations in Head and Neck Anatomy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2007, 30, 191-198.	1.3	33
187	Long-term outcomes after multidisciplinary management of T3 laryngeal squamous cell carcinomas: Improved functional outcomes and survival with modern therapeutic approaches. <i>Head and Neck</i> , 2016, 38, 1739-1751.	2.0	33
188	Merkel cell carcinoma of the head and neck: Favorable outcomes with radiotherapy. <i>Head and Neck</i> , 2016, 38, E452-8.	2.0	32
189	Improved setup and positioning accuracy using a three-point customized cushion/mask/bite-block immobilization system for stereotactic reirradiation of head and neck cancer. <i>Journal of Applied Clinical Medical Physics</i> , 2016, 17, 180-189.	1.9	32
190	Delayed lower cranial neuropathy after oropharyngeal intensity-modulated radiotherapy: A cohort analysis and literature review. <i>Head and Neck</i> , 2017, 39, 1516-1523.	2.0	32
191	Patterns-of-failure guided biological target volume definition for head and neck cancer patients: FDG-PET and dosimetric analysis of dose escalation candidate subregions. <i>Radiotherapy and Oncology</i> , 2017, 124, 248-255.	0.6	32
192	Design and fabrication of a 3D-printed oral stent for head and neck radiotherapy from routine diagnostic imaging. <i>3D Printing in Medicine</i> , 2017, 3, 12.	3.1	31
193	Risk of second primary malignancies in head and neck cancer patients treated with definitive radiotherapy. <i>Npj Precision Oncology</i> , 2019, 3, 22.	5.4	31
194	Tobacco exposure as a major modifier of oncologic outcomes in human papillomavirus (HPV) associated oropharyngeal squamous cell carcinoma. <i>BMC Cancer</i> , 2020, 20, 912.	2.6	31
195	Hypothyroidism in older patients with head and neck cancer after treatment with radiation: A population-based study. <i>Head and Neck</i> , 2009, 31, 1031-1038.	2.0	30
196	Creating customized oral stents for head and neck radiotherapy using 3D scanning and printing. <i>Radiation Oncology</i> , 2019, 14, 148.	2.7	30
197	Impact of Gender, Partner Status, and Race on Locoregional Failure and Overall Survival in Head and Neck Cancer Patients in Three Radiation Therapy Oncology Group Trials. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, e101-e109.	0.8	29
198	Depression and Oropharynx Cancer Outcome. <i>Psychosomatic Medicine</i> , 2016, 78, 38-48.	2.0	29

#	ARTICLE	IF	CITATIONS
199	Quantitative body mass characterization before and after head and neck cancer radiotherapy: A challenge of height-weight formulae using computed tomography measurement. <i>Oral Oncology</i> , 2016, 61, 62-69.	1.5	29
200	Development and validation of a 3D-printed bolus cap for total scalp irradiation. <i>Journal of Applied Clinical Medical Physics</i> , 2019, 20, 89-96.	1.9	29
201	Outcomes and toxicities following stereotactic ablative radiotherapy for pulmonary metastases in patients with primary head and neck cancer. <i>Head and Neck</i> , 2020, 42, 1939-1953.	2.0	29
202	Auto-segmentation of low-risk clinical target volume for head and neck radiation therapy. <i>Practical Radiation Oncology</i> , 2014, 4, e31-e37.	2.1	28
203	Prognostic value of p16 expression in Epstein-Barr virus-positive nasopharyngeal carcinomas. <i>Head and Neck</i> , 2016, 38, E1459-66.	2.0	28
204	Correlation Between the Severity of Cetuximab-Induced Skin Rash and Clinical Outcome for Head and Neck Cancer Patients: The ARTOG Experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 1346-1354.	0.8	28
205	Atlas ranking and selection for automatic segmentation of the esophagus from CT scans. <i>Physics in Medicine and Biology</i> , 2017, 62, 9140-9158.	3.0	28
206	Usefulness of surveillance imaging in patients with head and neck cancer who are treated with definitive radiotherapy. <i>Cancer</i> , 2019, 125, 1823-1829.	4.1	28
207	Outcomes of oral cavity cancer patients treated with surgery followed by postoperative intensity modulated radiation therapy. <i>Oral Oncology</i> , 2017, 72, 90-97.	1.5	28
208	Management of the lymph node-positive neck in the patient with human papillomavirus-associated oropharyngeal cancer. <i>Cancer</i> , 2014, 120, 3082-3088.	4.1	27
209	Prospective in silico study of the feasibility and dosimetric advantages of MRI-guided dose adaptation for human papillomavirus positive oropharyngeal cancer patients compared with standard IMRT. <i>Clinical and Translational Radiation Oncology</i> , 2018, 11, 11-18.	1.7	27
210	Comparing Intensity-Modulated Proton Therapy With Intensity-Modulated Photon Therapy for Oropharyngeal Cancer: The Journey From Clinical Trial Concept to Activation. <i>Seminars in Radiation Oncology</i> , 2018, 28, 108-113.	2.2	26
211	Long-term patient reported outcomes following radiation therapy for oropharyngeal cancer: cross-sectional assessment of a prospective symptom survey in patients ≥65 years old. <i>Radiation Oncology</i> , 2017, 12, 150.	2.7	25
212	Patient-reported outcomes of symptom burden in patients receiving surgical or nonsurgical treatment for low-intermediate risk oropharyngeal squamous cell carcinoma: A comparative analysis of a prospective registry. <i>Oral Oncology</i> , 2019, 91, 13-20.	1.5	25
213	Outcomes of carotid-sparing IMRT for T1 glottic cancer: Comparison with conventional radiation. <i>Laryngoscope</i> , 2020, 130, 146-153.	2.0	25
214	Reduced feeding tube duration with intensity-modulated radiation therapy for head and neck cancer: A Surveillance, Epidemiology, and End Results-Medicare Analysis. <i>Cancer</i> , 2017, 123, 283-293.	4.1	24
215	Chronic radiation-associated dysphagia in oropharyngeal cancer survivors: Towards age-adjusted dose constraints for deglutitive muscles. <i>Clinical and Translational Radiation Oncology</i> , 2019, 18, 16-22.	1.7	24
216	Prospective quantitative quality assurance and deformation estimation of MRI-CT image registration in simulation of head and neck radiotherapy patients. <i>Clinical and Translational Radiation Oncology</i> , 2019, 18, 120-127.	1.7	24

#	ARTICLE	IF	CITATIONS
217	Practice recommendations for risk-adapted head and neck cancer radiotherapy during the COVID-19 pandemic: An ASTRO-ESTRO consensus statement. <i>Radiotherapy and Oncology</i> , 2020, 151, 314-321.	0.6	24
218	A phase I/II study of neoadjuvant chemotherapy followed by radiation with boost chemotherapy for advanced T-stage nasopharyngeal carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 63, 717-724.	0.8	23
219	Radiation-associated head and neck sarcomas: Spectrum of imaging findings. <i>Oral Oncology</i> , 2012, 48, 155-161.	1.5	23
220	Disease control and toxicity outcomes using ruthenium eye plaque brachytherapy in the treatment of uveal melanoma. <i>Practical Radiation Oncology</i> , 2014, 4, e189-e194.	2.1	22
221	Disease control and toxicity outcomes for T4 carcinoma of the nasopharynx treated with intensity-modulated radiotherapy. <i>Head and Neck</i> , 2016, 38, E925-33.	2.0	22
222	Prospective Imaging Assessment of Mortality Risk After Head-and-Neck Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 667-674.	0.8	21
223	Favorable patient reported outcomes following IMRT for early carcinomas of the tonsillar fossa: Results from a symptom assessment study. <i>Radiotherapy and Oncology</i> , 2015, 117, 132-138.	0.6	21
224	Magnetic resonance imaging of swallowing-related structures in nasopharyngeal carcinoma patients receiving IMRT: Longitudinal dose-response characterization of quantitative signal kinetics. <i>Radiotherapy and Oncology</i> , 2016, 118, 315-322.	0.6	21
225	Xerostomia-related quality of life for patients with oropharyngeal carcinoma treated with proton therapy. <i>Radiotherapy and Oncology</i> , 2020, 142, 133-139.	0.6	21
226	Patient-reported outcomes, physician-reported toxicities, and treatment outcomes in a modern cohort of patients with sinonasal cancer treated using proton beam therapy. <i>Radiotherapy and Oncology</i> , 2020, 148, 258-266.	0.6	21
227	How to reduce radiation-related toxicity in patients with cancer of the head and neck. <i>Current Oncology Reports</i> , 2006, 8, 140-145.	4.0	20
228	<i>Medical Physics</i> , 2012, 39, 5136-5144.	3.0	20
229	Prospective assessment of an atlas-based intervention combined with real-time software feedback in contouring lymph node levels and organs-at-risk in the head and neck: Quantitative assessment of conformance to expert delineation. <i>Practical Radiation Oncology</i> , 2013, 3, 186-193.	2.1	20
230	Age-adjusted comorbidity and survival in locally advanced laryngeal cancer. <i>Head and Neck</i> , 2018, 40, 2060-2069.	2.0	20
231	Water bolus for electron irradiation of the ear canal. <i>International Journal of Radiation Oncology Biology Physics</i> , 1995, 33, 479-483.	0.8	19
232	A phase I study of fludarabine combined with radiotherapy in patients with intermediate to locally advanced head and neck squamous cell carcinoma. <i>Radiotherapy and Oncology</i> , 2002, 63, 187-193.	0.6	19
233	Mucositis: current management and investigations. <i>Seminars in Radiation Oncology</i> , 2003, 13, 267-273.	2.2	19
234	Patient reported dry mouth: Instrument comparison and model performance for correlation with quality of life in head and neck cancer survivors. <i>Radiotherapy and Oncology</i> , 2018, 126, 75-80.	0.6	19



#	ARTICLE	IF	CITATIONS
235	Radiographic retropharyngeal lymph node involvement in HPV-associated oropharyngeal carcinoma: Patterns of involvement and impact on patient outcomes. <i>Cancer</i> , 2019, 125, 1536-1546.	4.1	19
236	Postoperative radiation of free jejunal autografts in patients with advanced cancer of the head and neck. <i>Cancer</i> , 1995, 75, 2356-2360.	4.1	18
237	Management of Radiation-Induced Severe Anophthalmic Socket Contracture in Patients With Uveal Melanoma. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2012, 28, 208-212.	0.8	18
238	Nomogram for Predicting Symptom Severity during Radiation Therapy for Head and Neck Cancer. <i>Otolaryngology - Head and Neck Surgery</i> , 2014, 151, 619-626.	1.9	18
239	Quantitative pretreatment CT volumetry: Association with oncologic outcomes in patients with T4a squamous carcinoma of the larynx. <i>Head and Neck</i> , 2017, 39, 1609-1620.	2.0	18
240	Prognostic impact of leukocyte counts before and during radiotherapy for oropharyngeal cancer. <i>Clinical and Translational Radiation Oncology</i> , 2017, 7, 28-35.	1.7	18
241	Outcomes of patients diagnosed with carcinoma metastatic to the neck from an unknown primary source and treated with intensity-modulated radiation therapy. <i>Cancer</i> , 2018, 124, 1415-1427.	4.1	18
242	Significance of Negative Posttreatment 18-FDG PET/CT Imaging in Patients With p16/HPV-Positive Oropharyngeal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 1029-1035.	0.8	18
243	Lymphopenia during radiotherapy in patients with oropharyngeal cancer. <i>Radiotherapy and Oncology</i> , 2020, 145, 95-100.	0.6	18
244	Clinical Implication of Diagnostic and Histopathologic Discrepancies in Sinonasal Malignancies. <i>Laryngoscope</i> , 2021, 131, E1468-E1475.	2.0	18
245	Intensity-modulated proton therapy for oropharyngeal cancer reduces rates of late xerostomia. <i>Radiotherapy and Oncology</i> , 2021, 160, 32-39.	0.6	18
246	Comprehensive Quantitative Evaluation of Variability in Magnetic Resonance-Guided Delineation of Oropharyngeal Gross Tumor Volumes and High-Risk Clinical Target Volumes: An R-IDEAL Stage 0 Prospective Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 426-436.	0.8	18
247	Interdigitating versus concurrent chemotherapy and radiotherapy for limited small cell lung cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 1995, 31, 807-811.	0.8	17
248	Clinical evaluation of the intraoral fluoride releasing system in radiation-induced xerostomic subjects. Part 2: Phase I study. <i>Oral Oncology</i> , 2006, 42, 946-953.	1.5	17
249	Longitudinal oncology registry of head and neck carcinoma (LORHAN®): initial supportive care findings. <i>Supportive Care in Cancer</i> , 2009, 17, 1393-401.	2.2	17
250	The Never-Ending Story: Finding a Role for Neoadjuvant Chemotherapy in the Management of Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 2685-2686.	1.6	17
251	Radiation therapy (with or without neck surgery) for phenotypic human papillomavirus-associated oropharyngeal cancer. <i>Cancer</i> , 2016, 122, 1702-1707.	4.1	17
252	Prognostic value of pretherapy platelet elevation in oropharyngeal cancer patients treated with chemoradiation. <i>International Journal of Cancer</i> , 2016, 138, 1290-1297.	5.1	17

#	ARTICLE	IF	CITATIONS
253	Prognostic significance of pre-treatment neutrophil-to-lymphocyte ratio (NLR) in patients with oropharyngeal cancer treated with radiotherapy. <i>British Journal of Cancer</i> , 2021, 124, 628-633.	6.4	17
254	ORGAN PRESERVATION FOR CARCINOMA OF THE LARYNX AND HYPOPHARYNX. <i>Hematology/Oncology Clinics of North America</i> , 2001, 15, 243-260.	2.2	16
255	The Influence of Diabetes Mellitus and Metformin on Distant Metastases in Oropharyngeal Cancer: A Multicenter Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 523-531.	0.8	16
256	Recurrent oral cavity cancer: Patterns of failure after salvage multimodality therapy. <i>Head and Neck</i> , 2017, 39, 633-638.	2.0	16
257	Fatigue following radiation therapy in nasopharyngeal cancer survivors: A dosimetric analysis incorporating patient report and observer rating. <i>Radiotherapy and Oncology</i> , 2019, 133, 35-42.	0.6	16
258	Postoperative Intensity-Modulated Proton Therapy for Head and Neck Adenoid Cystic Carcinoma. <i>International Journal of Particle Therapy</i> , 2016, 2, 533-543.	1.8	16
259	Salivary flow rates measured during radiation therapy in head and neck cancer patients: A pilot study assessing salivary sediment formation. <i>Journal of Prosthetic Dentistry</i> , 2008, 100, 142-146.	2.8	15
260	Outcomes of patients with tonsillar carcinoma treated with posttonsillectomy radiation therapy. <i>Head and Neck</i> , 2010, 32, 473-480.	2.0	15
261	Looking Beyond the Numbers: Highlighting the Challenges of Population-Based Studies in Cancer Research. <i>Journal of Clinical Oncology</i> , 2016, 34, 2317-2318.	1.6	15
262	Clinical outcomes after local field conformal reirradiation of patients with retropharyngeal nodal metastasis. <i>Head and Neck</i> , 2017, 39, 2079-2087.	2.0	15
263	Postoperative local-regional radiation therapy in the treatment of parathyroid carcinoma: The MD Anderson experience of 35 years. <i>Practical Radiation Oncology</i> , 2017, 7, e463-e470.	2.1	15
264	Decreased gastrostomy tube incidence and weight loss after transoral robotic surgery for low to intermediate risk oropharyngeal squamous cell carcinoma. <i>Head and Neck</i> , 2018, 40, 2507-2513.	2.0	15
265	Stereotactic body ablative radiotherapy for reirradiation of small volume head and neck cancers is associated with prolonged survival: Large, single institution, modern cohort study. <i>Head and Neck</i> , 2021, 43, 3331-3344.	2.0	15
266	Outcomes for hypopharyngeal carcinoma treated with organ preservation therapy. <i>Head and Neck</i> , 2016, 38, E2091-9.	2.0	14
267	Predicting treatment Response based on Dual assessment of magnetic resonance Imaging kinetics and Circulating Tumor cells in patients with Head and Neck cancer (PREDICT-HN): matching liquid biopsy and quantitative tumor modeling. <i>BMC Cancer</i> , 2018, 18, 903.	2.6	14
268	A prospective longitudinal assessment of MRI signal intensity kinetics of non-target muscles in patients with advanced stage oropharyngeal cancer in relationship to radiotherapy dose and post-treatment radiation-associated dysphagia: Preliminary findings from a randomized trial. <i>Radiotherapy and Oncology</i> , 2019, 130, 46-55.	0.6	14
269	Highly conformal reirradiation in patients with prior oropharyngeal radiation: Clinical efficacy and toxicity outcomes. <i>Head and Neck</i> , 2020, 42, 3326-3335.	2.0	14
270	Determinants of patient-reported xerostomia among long-term oropharyngeal cancer survivors. <i>Cancer</i> , 2021, 127, 4470-4480.	4.1	14

#	ARTICLE	IF	CITATIONS
271	Total Midface Reconstruction After Radical Tumor Resection. <i>Annals of Plastic Surgery</i> , 1996, 36, 551-557.	0.9	13
272	Clinical evaluation of the intraoral fluoride releasing system in radiation-induced xerostomic subjects. Part 1: Fluorides. <i>Oral Oncology</i> , 2006, 42, 934-945.	1.5	13
273	CT Findings in Temporal Bone Osteoradionecrosis. <i>Journal of Computer Assisted Tomography</i> , 2014, 38, 662-666.	0.9	13
274	Estimation of daily interfractional larynx residual setup error after isocentric alignment for head and neck radiotherapy: quality assurance implications for target volume and organs at risk margination using daily CT on rails imaging. <i>Journal of Applied Clinical Medical Physics</i> , 2015, 16, 159-169.	1.9	13
275	Characteristics and kinetics of cervical lymph node regression after radiation therapy for human papillomavirus-associated oropharyngeal carcinoma: Quantitative image analysis of post-radiotherapy response. <i>Oral Oncology</i> , 2015, 51, 195-201.	1.5	13
276	Radiation-associated malignancies of the ear canal and temporal bone. <i>Laryngoscope</i> , 2015, 125, 1198-1204.	2.0	12
277	Minocycline for symptom reduction during radiation therapy for head and neck cancer: a randomized clinical trial. <i>Supportive Care in Cancer</i> , 2020, 28, 261-269.	2.2	12
278	Estimating PTV Margins in Head and Neck Stereotactic Ablative Radiation Therapy (SABR) Through Target Site Analysis of Positioning and Intrafractional Accuracy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 185-193.	0.8	12
279	Outcomes after salvage for HPV-positive recurrent oropharyngeal cancer treated with primary radiation. <i>Oral Oncology</i> , 2021, 113, 105125.	1.5	12
280	Bioelectrical impedance analysis as a quantitative measure of sarcopenia in head and neck cancer patients treated with radiotherapy. <i>Radiotherapy and Oncology</i> , 2021, 159, 21-27.	0.6	12
281	To TORS or Not to TORS: But Is That the Question?. <i>JAMA Otolaryngology</i> , 2010, 136, 1085.	1.2	11
282	Anisotropic Margin Expansions in 6 Anatomic Directions for Oropharyngeal Image Guided Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 596-601.	0.8	11
283	Reply to B. O'Sullivan et al. <i>Journal of Clinical Oncology</i> , 2015, 33, 1708-1709.	1.6	11
284	Comparison of systemic therapies used concurrently with radiation for the treatment of human papillomavirus-associated oropharyngeal cancer. <i>Head and Neck</i> , 2016, 38, E1554-61.	2.0	11
285	The impact of tongue-deviating and tongue-depressing oral stents on long-term radiation-associated symptoms in oropharyngeal cancer survivors. <i>Clinical and Translational Radiation Oncology</i> , 2020, 24, 71-78.	1.7	11
286	Outcomes after radiation therapy for T2N0/stage II glottic squamous cell carcinoma. <i>Head and Neck</i> , 2020, 42, 2791-2800.	2.0	11
287	Prospective longitudinal patient-reported outcomes of swallowing following intensity modulated proton therapy for oropharyngeal cancer. <i>Radiotherapy and Oncology</i> , 2020, 148, 133-139.	0.6	11
288	Proton Therapy for HPV-Associated Oropharyngeal Cancers of the Head and Neck: a De-Intensification Strategy. <i>Current Treatment Options in Oncology</i> , 2021, 22, 54.	3.0	11

#	ARTICLE	IF	CITATIONS
289	Work Outcomes after Intensity-Modulated Proton Therapy (IMPT) versus Intensity-Modulated Photon Therapy (IMRT) for Oropharyngeal Cancer. <i>International Journal of Particle Therapy</i> , 2021, 8, 319-327.	1.8	11
290	Knowledge-based planning for the radiation therapy treatment plan quality assurance for patients with head and neck cancer. <i>Journal of Applied Clinical Medical Physics</i> , 2022, 23, e13614.	1.9	11
291	Results of a changing treatment philosophy for children with stage I Hodgkin's disease: A 35-year experience. <i>Medical and Pediatric Oncology</i> , 1991, 19, 214-220.	1.0	10
292	Is There Still a Role for Induction Chemotherapy for Head and Neck Cancer?. <i>Journal of Clinical Oncology</i> , 2005, 23, 1059-1060.	1.6	10
293	Head and neck radiation and mucositis. <i>Current Opinion in Supportive and Palliative Care</i> , 2007, 1, 30-34.	1.3	10
294	Orbital carcinomas treated with adjuvant intensity-modulated radiation therapy. <i>Head and Neck</i> , 2016, 38, E580-7.	2.0	10
295	Outcomes and patterns of radiation associated brain image changes after proton therapy for head and neck skull base cancers. <i>Radiotherapy and Oncology</i> , 2020, 151, 119-125.	0.6	10
296	Comparison of tumor delineation using dual energy computed tomography versus magnetic resonance imaging in head and neck cancer re-irradiation cases. <i>Physics and Imaging in Radiation Oncology</i> , 2020, 14, 1-5.	2.9	9
297	Risk and Clinical Risk Factors Associated With Late Lower Cranial Neuropathy in Long-term Oropharyngeal Squamous Cell Carcinoma Survivors. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2021, 147, 469.	2.2	9
298	Psychosocial and Economic Impact of Cancer. <i>Dental Clinics of North America</i> , 2008, 52, 231-252.	1.8	8
299	Patterns of locoregional failure following post-operative intensity-modulated radiotherapy to oral cavity cancer: quantitative spatial and dosimetric analysis using a deformable image registration workflow. <i>Radiation Oncology</i> , 2017, 12, 129.	2.7	8
300	Circulating BRAF V600E Cell-Free DNA as a Biomarker in the Management of Anaplastic Thyroid Carcinoma. <i>JCO Precision Oncology</i> , 2018, 2, 1-11.	3.0	8
301	The role of salvage surgery with interstitial brachytherapy for the Management of Regionally Recurrent Head and Neck Cancers. <i>Cancers of the Head &amp; Neck</i> , 2019, 4, 4.	6.2	8
302	Surveillance imaging for patients with head and neck cancer treated with definitive radiotherapy: A partially observed Markov decision process model. <i>Cancer</i> , 2020, 126, 749-756.	4.1	8
303	Patterns of Failure After Intensity Modulated Radiation Therapy in Head and Neck Squamous Cell Carcinoma of Unknown Primary: Implication of Elective Nodal and Mucosal Dose Coverage. <i>Advances in Radiation Oncology</i> , 2020, 5, 929-935.	1.2	8
304	Proton Therapy for Head and Neck Cancer: A 12-Year, Single-Institution Experience. <i>International Journal of Particle Therapy</i> , 2021, 8, 108-118.	1.8	8
305	Concurrent epithelioid malignant peripheral nerve sheath tumor and papillary thyroid carcinoma in the treated field of Hodgkin's disease. <i>Head and Neck</i> , 2008, 30, 675-679.	2.0	7
306	CT-based volumetric tumor growth velocity: A novel imaging prognostic indicator in oropharyngeal cancer patients receiving radiotherapy. <i>Oral Oncology</i> , 2016, 63, 16-22.	1.5	7

#	ARTICLE	IF	CITATIONS
307	Fabrication of an unconventional bolus-type stent for a combined intraoral/extraoral defect treated with proton radiation therapy. <i>Journal of Prosthetic Dentistry</i> , 2017, 117, 563-565.	2.8	7
308	Patient Outcomes after Reirradiation of Small Skull Base Tumors using Stereotactic Body Radiotherapy, Intensity Modulated Radiotherapy, or Proton Therapy. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2020, 81, 638-644.	0.8	7
309	A Dosimetric Comparison of Oral Cavity Sparing in the Unilateral Treatment of Early Stage Tonsil Cancer: IMRT, IMPT, and Tongue-Deviating Oral Stents. <i>Advances in Radiation Oncology</i> , 2020, 5, 1359-1363.	1.2	7
310	Longitudinal characterization of the tumoral microbiome during radiotherapy in HPV-associated oropharynx cancer. <i>Clinical and Translational Radiation Oncology</i> , 2021, 26, 98-103.	1.7	7
311	The impact of induction and/or concurrent chemoradiotherapy on acute and late patient-reported symptoms in oropharyngeal cancer: Application of a mixed model analysis of a prospective observational cohort registry. <i>Cancer</i> , 2021, 127, 2453-2464.	4.1	7
312	Where are the at-risk cervical nodes?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 58, 1-2.	0.8	6
313	Erratum to "Clinical evaluation of the intraoral fluoride releasing system in radiation-induced xerostomic subjects. Part 2: Phase I study". <i>Oral Oncology</i> , 2007, 43, 98-105.	1.5	6
314	Three-dimensional imaging assessment of anatomic invasion and volumetric considerations for chemo/radiotherapy-based laryngeal preservation in T3 larynx cancer. <i>Oral Oncology</i> , 2018, 79, 1-8.	1.5	6
315	Stereotactic radiosurgery for trigeminal pain secondary to recurrent malignant skull base tumors. <i>Journal of Neurosurgery</i> , 2019, 130, 812-821.	1.6	6
316	A prospective parallel design study testing non-inferiority of customized oral stents made using 3D printing or manually fabricated methods. <i>Oral Oncology</i> , 2020, 106, 104665.	1.5	6
317	<sup>18</sup> F-FDG positron emission tomography mining for metabolic imaging biomarkers of radiation-induced xerostomia in patients with oropharyngeal cancer. <i>Clinical and Translational Radiation Oncology</i> , 2021, 29, 93-101.	1.7	6
318	Unilateral Radiotherapy for Tonsillar Cancer: Treatment Outcomes in the Era of Human Papilloma Virus (HPV), Positron-emission Tomography (PET) and Intensity-modulated Radiation Therapy (IMRT). <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, , .	0.8	6
319	Impact of changes to the American Joint Committee on Cancer T classification on outcome prediction in patients with oropharyngeal cancer. <i>Cancer</i> , 2006, 106, 1950-1957.	4.1	5
320	Clinical characteristics of patients with multiple potentially human papillomavirus-related malignancies. <i>Head and Neck</i> , 2014, 36, 819-825.	2.0	5
321	Predicting oropharyngeal tumor volume throughout the course of radiation therapy from pretreatment computed tomography data using general linear models. <i>Medical Physics</i> , 2014, 41, 051705.	3.0	5
322	Larynx and Hypopharynx Cancer. , 2016, , 649-672.e4.		5
323	Cognitive function and patient-reported memory problems after radiotherapy for cancers at the skull base: A cross-sectional survivorship study using the Telephone Interview for Cognitive Status and the MD Anderson Symptom Inventory-Head and Neck Module. <i>Head and Neck</i> , 2017, 39, 2048-2056.	2.0	5
324	Prospective observational evaluation of radiation-induced late taste impairment kinetics in oropharyngeal cancer patients: Potential for improvement over time?. <i>Clinical and Translational Radiation Oncology</i> , 2020, 22, 98-105.	1.7	5

#	ARTICLE	IF	CITATIONS
325	The impact of age on outcome in phase III NRG Oncology/RTOG trials of radiotherapy (XRT) +/â systemic therapy in locally advanced head and neck cancer. <i>Journal of Geriatric Oncology</i> , 2021, 12, 937-944.	1.0	5
326	Association of Risk Factors With Patient-Reported Voice and Speech Symptoms Among Long-term Survivors of Oropharyngeal Cancer. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2021, 147, 615.	2.2	5
327	Two-field versus three-field irradiation technique in the postoperative treatment of head-and-neck cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 469-476.	0.8	4
328	Development and validation of a contouring guideline for the taste bud bearing tongue mucosa. <i>Radiotherapy and Oncology</i> , 2021, 157, 63-69.	0.6	4
329	Proton Therapy for Major Salivary Gland Cancer: Clinical Outcomes. <i>International Journal of Particle Therapy</i> , 2021, 8, 261-272.	1.8	4
330	Proton Beam Therapy for Head and Neck Carcinoma of Unknown Primary: Toxicity and Quality of Life. <i>International Journal of Particle Therapy</i> , 2021, 8, 234-247.	1.8	4
331	Activity-Based Costing of Intensity-Modulated Proton versus Photon Therapy for Oropharyngeal Cancer. <i>International Journal of Particle Therapy</i> , 2021, 8, 374-382.	1.8	4
332	Weekly paclitaxel, carboplatin, cetuximab (PCC), and cetuximab, docetaxel, cisplatin, and fluorouracil (C-TPF), followed by risk-based local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma (LAHNSCC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 6001-6001.	1.6	4
333	ECOG-ACRIN 1308: Commentary on a Negative Phase II Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 1969-1970.	1.6	3
334	Not All 30-Gy Regimens Are Equal. <i>Journal of Clinical Oncology</i> , 2019, 37, 3558-3559.	1.6	3
335	A prospective evaluation of healthârelated quality of life after skull base reâirradiation. <i>Head and Neck</i> , 2020, 42, 485-497.	2.0	3
336	Neurologic sequelae following radiation with and without chemotherapy for oropharyngeal cancer: Patient reported outcomes study. <i>Head and Neck</i> , 2020, 42, 2137-2144.	2.0	3
337	SABR for Skull Base Malignancies: A Systematic Analysis of Set-Up and Positioning Accuracy. <i>Practical Radiation Oncology</i> , 2020, 10, 363-371.	2.1	3
338	Defining the doseâvolume criteria for laryngeal sparing in locally advanced oropharyngeal cancer utilizing splitâfield IMRT, wholeâfield IMRT and VMAT. <i>Journal of Applied Clinical Medical Physics</i> , 2021, 22, 37-44.	1.9	3
339	Proton Image-guided Radiation Assignment for Therapeutic Escalation via Selection of locally advanced head and neck cancer patients [PIRATES]: A Phase I safety and feasibility trial of MRI-guided adaptive particle radiotherapy. <i>Clinical and Translational Radiation Oncology</i> , 2022, 32, 35-40.	1.7	3
340	Association of hearing loss and tinnitus symptoms with <sc>healthârelated</sc> quality of life among <sc>longâterm</sc> oropharyngeal cancer survivors. <i>Cancer Medicine</i> , 0, , .	2.8	3
341	Forecasting longitudinal changes in oropharyngeal tumor morphology throughout the course of head and neck radiation therapy. <i>Medical Physics</i> , 2014, 41, 081708.	3.0	2
342	In Regard to Routman etÂal. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 1295-1296.	0.8	2



#	ARTICLE	IF	CITATIONS
343	Optimizing laryngeal sparing with intensity modulated radiotherapy or volumetric modulated arc therapy for unilateral tonsil cancer. <i>Physics and Imaging in Radiation Oncology</i> , 2019, 10, 29-34.	2.9	2
344	Postoperative Radiation Therapy for Metastatic Cervical Adenopathy. <i>Seminars in Radiation Oncology</i> , 2019, 29, 144-149.	2.2	2
345	Conditional survival among patients with oropharyngeal cancer treated with radiation therapy and alive without recurrence 5 years after diagnosis. <i>Cancer</i> , 2021, 127, 1228-1237.	4.1	2
346	Patient-Reported Outcomes after Intensity-Modulated Proton Therapy for Oropharynx Cancer. <i>International Journal of Particle Therapy</i> , 2021, 8, 213-222.	1.8	2
347	Larynx and Hypopharynx Cancer. , 2012, , 639-663.		2
348	Risk factors associated with patient-reported fatigue among long-term oropharyngeal carcinoma survivors. <i>Head and Neck</i> , 2022, 44, 952-963.	2.0	2
349	Genetic susceptibility to patient-reported xerostomia among long-term oropharyngeal cancer survivors. <i>Scientific Reports</i> , 2022, 12, 6662.	3.3	2
350	41 Concomitant boost radiotherapy for squamous carcinoma of the tonsillar fossa. <i>International Journal of Radiation Oncology Biology Physics</i> , 1995, 32, 161.	0.8	1
351	In Regard to Kjems et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 240.	0.8	1
352	Reply to radiotherapy for human papillomavirus-positive oropharyngeal cancers in the National Cancer Data Base. <i>Cancer</i> , 2016, 122, 3411-3412.	4.1	1
353	Surgical Treatment for T4 Oropharyngeal Cancer. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2017, 143, 96.	2.2	1
354	Factors associated with complex oral treatment device usage in patients with head and neck cancer. <i>Clinical and Translational Radiation Oncology</i> , 2021, 30, 78-83.	1.7	1
355	Xerostomia. , 2007, , 185-199.		1
356	Carcinoma of the Paranasal Sinuses and Olfactory Neuroblastoma. , 2005, , 371-384.		1
357	The influence of radiation dose on taste impairment in a prospective observational study cohort of oropharyngeal cancer patients. <i>Acta Oncologica</i> , 2022, 61, 146-152.	1.8	1
358	Phase II study of polymyxin B, tobramycin, and clotrimazole to prevent oral irradiation mucositis. <i>Radiation Oncology Investigations</i> , 1996, 4, 23-26.	0.9	0
359	New equations for matching a low neck field to oblique upper neck fields with collimator rotation in a 3-field monoisocentric setup for head-and-neck cancers. <i>Medical Dosimetry</i> , 2004, 29, 86-91.	0.9	0
360	Oral Complications of Cancer Therapy. , 2006, , 1349-1362.		0

#	ARTICLE	IF	CITATIONS
361	Response to Letter by Dr. Ibott et al.. International Journal of Radiation Oncology Biology Physics, 2010, 76, 639.	0.8	0
362	Comparing surgery and radiation in the treatment of oropharyngeal cancer. Head and Neck, 2012, 34, 1198-1199.	2.0	0
363	Letter to the Editor regarding transoral laser microsurgery followed by radiotherapy in advanced oropharyngeal cancer. Head and Neck, 2014, 36, 1674-1675.	2.0	0
364	Reply to D. Adkins et al. Journal of Clinical Oncology, 2015, 33, 1224-1225.	1.6	0
365	In Regard to Arthurs etÂal. International Journal of Radiation Oncology Biology Physics, 2017, 97, 440.	0.8	0
366	Transoral Robotic Surgery-Assisted Endoscopy. JAMA Otolaryngology - Head and Neck Surgery, 2017, 143, 1058.	2.2	0
367	In Regard to Sher et al. Practical Radiation Oncology, 2018, 8, 66-67.	2.1	0
368	Regular Olâ€™™ Intensity. International Journal of Radiation Oncology Biology Physics, 2020, 107, 615.	0.8	0
369	SU-E-J-138: The Effect of Shoulder Variation on IMRT and SmartArc Plans for Head and Neck Cancer. Medical Physics, 2011, 38, 3474-3474.	3.0	0
370	Postoperative Intensity-Modulated Radiation Therapy for Head and Neck Cancers: A Case-Based Review. , 2015, , 193-213.		0
371	Primary Mucosal Melanomas of the Head and Neck. , 2016, , 641-656.		0
372	Transoral Surgery With Neck Dissection Is an Excellent Treatment for the Appropriately Selected Patient With Early-Stage Oropharyngeal Cancer. Journal of Clinical Oncology, 2022, 40, 1132-1133.	1.6	0
373	Feasibility of Mobile and Sensor Technology for Remote Monitoring in Cancer Care and Prevention.. AMIA ... Annual Symposium proceedings, 2021, 2021, 979-988.	0.2	0